A protein in the
may link smoking and diabetes
overrides the communication pathway between the
and pancreas, causing high
levels in rats
Megha Satyanarayana
OCTOBER 16, 2019 | APPEARED IN VOLUME 97, ISSUE 41
Smokers develop type 2 diabetes 30–40% more often than nonsmokers, and new research suggests that
’s actions in the
may be to blame.
Experiments in rats suggest that
may needlessly turn on part of the body’s fight-or-flight mechanism, flooding it with useless
that would
get used to run, punch, or kick.
years of cigarette or
-pen use, those useless
bumps wear out the insulin-
signalingany nonverbal action or gesture that encodes a message
pathways in cells and eventually lead to diabetes, says Paul J. Kenny, the
at the Icahn School of Medicine at Mount Sinai who led the study (Nature 2019, DOI: 10.1038/s41586-019-1653-x).
Kenny’s
found that the main player in
signalingany nonverbal action or gesture that encodes a message
short circuit is a protein called TCF7L2, which influences two things: the motivation to take
and a conversation between the
and pancreas.
“It all converges on
one
,” Kenny says. “Ultimately, a disease like diabetes may be originating in the
or may reflect
-body interactions, and I think that’s absolutely fascinating and absolutely terrifying.” He wonders if other diseases have
-body connections that can get
disrupted.
His
studies a part of the
called the
, which is involved in our stress response and is chock full of
receptors, which
binds to and activates, giving people a buzz when they smoke. Kenny’s group had previously reported that mutations that seem to lead to
addiction in humans were often found in
receptors in the
.
Credit: Wikipedia/Emw
TCF7L2 is a
in the
and pancreas.
The
is
full of TCF7L2, which is a
that acts as an on-off switch for several genes. Rats missing
“consume absolutely horrendous amounts of
,” Kenny says.
But TCF7L2 is
expressed elsewhere in the body and is associated with type 2 diabetes. People with certain gene sequences for TCF7L2 tend to get diabetes more often than people with other sequences. Kenny says his
thought TCF7L2 might be doing something in both the
and pancreas to influence the role of
in diabetes. The researchers found that after
exposure, the
receptors in rats without TCF7L2 were less sensitive than those of normal rats. Under normal conditions, when
or other molecules turn on the receptors, the proteins eventually enter a
state in which the receptors can’t turn back on for some time. In rats without TCF7L2, the receptors couldn’t bounce back from
state as quickly as ones in rats with TCF7L2. Basically, their brains weren’t responding in quite the same way, Kenny says. And in an experiment that traced the path of neurons, the
found that neurons in the pancreas led to the
.
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
Looking at different genes in the
that TCF7L2 is predicted to control, the
found that many were involved in the regulation of
metabolism. Given that
is known to cause increases
-
levels, the
wondered if TCF7L2 might influence
action of
. Lowering levels of TCF7L2 reduced
’s ability to boost blood sugar. And after treating rats for 21 days with
, the
found that the rats missing TCF7L2 had lower blood-sugar levels, suggesting that the
mediates some diabetes-like symptoms.
Kenny doesn’t think that high blood-
levels lead to
addiction.
, it’s more likely that all the extra
is tamping down the activity of
receptors, making each puff less effective and leading people to take more puffs. He says one of the
big questions is whether the
is playing a role in normal
metabolism.
Kenny thinks the link between the stress-response function of the
and the
might lead to diabetes. In an actual fight-or-flight situation, “you’re stressed or you’re frightened, and you need to respond to that,” he says. “You need to access energy reserves, and
stress affects the pancreas.” Over time,
regular stress to the pancreas leads to diabetes. TCF7L2 helps regulate all that.
The
is now looking at drugs that modulate TCF7L2 activity directly or indirectly. One is
, sold as Januvia. It’s a diabetes drug that prevents the breakdown of a protein called GLP-1, which is associated with TCF7L2. Mice given the drug tend to consume less
, and Kenny says there are some anecdotal data that people taking Januvia stop smoking (Nat. Neurosci. 2017, DOI: 10.1038/nn.4540). There are several other drugs in
class, and Kenny thinks these drugs might make an excellent one-two punch in people who have diabetes and may want to stop smoking.
Marina Picciotto, a neuroscientist at Yale School of Medicine who was not involved in the research, says these experiments not only define a new way that the
communicates with the body and vice
help pinpoint how
and smoking affect metabolism by overtaking
conversation.
SPONSORED CONTENT
New, Safer Automated Analysis of Ethylene Oxide
Metrohm
Rats are a fairly reliable model for
use and overuse, she says, but it remains to be seen if the same things are happening in humans. Kenny’s
is looking at large databases of human genetics, searching for people who might have mutations in TCF7L2 and seeing whether they smoke and if they ever developed diabetes.
There are “all sorts of interactions between [TCF7L2], smoking, and diabetes from human
data,” he says. “
is a major driver of both
and body diseases. It’s a very problematic drug.”